Stage 3: Proof of Concept
In the short-term, they estimate that the device has the potential to affect 10,000 neonates in Malawi; in the long-term, they estimate it will affect nearly 2 million neonates in the developing world. As they expand their study of Neosyp in the long-term to explore its use in the treatment of hypertensive disorders of pregnancy, ischemic heart disease, and cancer treatment, they estimate the device will improve care for nearly 10.5 million people in the developing world.
Funds Raised to Date
Low Cost Mechanical Syringe Pump to Regulate IV-Fluid Delivery in Low-Resource Settings
How does your innovation work?
In this one-year project, Rice University will perform real-world viability testing of the NeoSyp in Malawi. They will conduct a clinical evaluation of Neosyp to assess the impact of the device on neonatal and pediatric care, implement training programs at district hospitals in the use of the device, engineer a refined Neosyp device for commercial manufacture, and work with stakeholders to develop a proposal for country-wide scale up of the device in Malawi.